ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Results of Operations and Financial Condition

ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02.

Results of Operations and Financial
Condition.

On March30, 2017, Aldeyra Therapeutics, Inc. (Aldeyra) issued a
press release and is holding a conference call regarding its
financial results for the year ended December31, 2016. The press
release is furnished as Exhibit 99.1 to this Current Report on
Form8-K and is
incorporated by reference herein.

Various statements
to be made during the conference call are forward-looking
statements under the securities laws, including, but not limited
to, statements regarding Aldeyras plans for its product
candidates. In some cases, you can identify forward looking
statements by terms such as, but not limited to, may, might,
will, objective, intend, should, could, can, would, expect,
believe, anticipate, project, target, design, estimate, predict,
potential, plan or the negative of these terms, and similar
expressions intended to identify forward-looking statements.Such
forward- looking statements are based upon current expectations
that involve risks, changes in circumstances, assumptions and
uncertainties.

Aldeyra is at an
early stage of development and may not ever have any products
that generate significant revenue. Important factors that could
cause actual results to differ materially from those reflected in
Aldeyras forward-looking statements include, among others, the
timing of enrollment, commencement and completion of Aldeyras
clinical trials, the timing and success of preclinical studies
and clinical trials conducted by Aldeyra and its development
partners; the ability to obtain and maintain regulatory approval
to conduct clinical trials and to commercialize Aldeyras product
candidates, and the labeling for any approved products; the
scope, progress, expansion, and costs of developing and
commercializing Aldeyras product candidates; the size and growth
of the potential markets for Aldeyras product candidates and the
ability to serve those markets; Aldeyras expectations regarding
Aldeyras expenses and revenue, the sufficiency of Aldeyras cash
resources and needs for additional financing; the rate and degree
of market acceptance of any of Aldeyras product candidates;
Aldeyras expectations regarding competition; Aldeyras anticipated
growth strategies; Aldeyras ability to attract or retain key
personnel; the anticipated trends and challenges in Aldeyras
business and the market in which it operates; and other factors
that are described in the Risk Factors and Managements Discussion
and Analysis of Financial Condition and Results of Operations
sections of Aldeyras Annual Report on Form 10-K for the year ended
December31, 2015 and Aldeyras Quarterly Report on Form 10-Q for
the quarter ended September30, 2016, which are on file with the
Securities and Exchange Commission (SEC) and available on the
SECs website at www.sec.gov. Additional information will also be
set forth in those sections of Aldeyras Annual Report on Form
10-K for the year ended December31, 2016, which will be filed
with the SEC in the first quarter of 2017.

In addition to the risks
described above and in Aldeyras other filings with the SEC, other
unknown or unpredictable factors also could affect Aldeyras
results.No forward-looking statements can be guaranteed and
actual results may differ materially from such statements.The
information conveyed on the conference call is provided only as
of the date of the call, and Aldeyra undertakes no obligation to
update any forward-looking statements presented on the call on
account of new information, future events, or otherwise, except
as required by law.

The information in Item 2.02
of this Current Report on Form 8-K and the Exhibit attached
hereto shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended (the Securities Act), or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

Item9.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.

Description

99.1 Press Release of Aldeyra Therapeutics, Inc. dated March30,
2017


About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Recent Trading Information

ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) closed its last trading session up +0.05 at 5.20 with 8,900 shares trading hands.

An ad to help with our costs